BrickBio Achieves Stable Cell Line in Record Timeframe: 5x Faster with 7x Enhanced Production
BOSTON, February 7, 2023 /PRNewswire/ -- BrickBio Highlights Unique Advantages from the Proprietary "VADER" System, published on Dec 22,...
BrickBio Achieves Stable Cell Line in Record Timeframe: 5x Faster with 7x Enhanced Production
BrickBio Unveils Powerful Engineered RNA Therapeutic Modification Platform at AACR 2022
BrickBio Announces Rapid V2, eCLIC™, Chemistry and Cytokine External Partner Collaboration
World's First Antibody Drug Conjugate (ADC) Rapid Predictive SiteSelect™ Panel Launched
BrickBio Creates Novel Class of Bispecific Antibody Drug Conjugate and Receives Green Light
BrickBio Enters into Antibody Drug Conjugate (ADC) Co-Development Partnership with Large Pharma
BrickBio Announces Data on First Preclinical Antibody for Breast and Gastric Cancer
BrickBio Validates Its Novel Therapeutic Conjugation Platform at Commercial Scale
BrickBio Expands Space to Accommodate Pharma Partnerships and Pipeline Development
Abcam & BrickBio announce partnership to incorporate conjugation-ready sites across Abcam portfolio
BrickBio Presents Novel Conjugation Chemistry & Unveiled Protein Therapeutic Program at World ADC
Dr. James Italia Joins BrickBio as Vice President of Commercial Development
BrickBio Obtains Exclusive License to “Pan Epitope” Site-Specific Antibody and Protein Modification